about
Carrageenan is a potent inhibitor of papillomavirus infectionQuantitation of human seroresponsiveness to Merkel cell polyomavirusMerkel cell polyomavirus and two previously unknown polyomaviruses are chronically shed from human skinHuman Merkel cell polyomavirus infection II. MCV is a common human infection that can be detected by conformational capsid epitope immunoassaysMaturation of the Human Papillomavirus 16 CapsidBromodomain protein Brd4 plays a key role in Merkel cell polyomavirus DNA replicationDNA from KI, WU and Merkel cell polyomaviruses is not detected in childhood central nervous system tumours or neuroblastomas.Adsorption of human papillomavirus 16 to live human sperm.The human immunodeficiency virus type 1 gag gene encodes an internal ribosome entry site.Maturation of papillomavirus capsids.Taxonomical developments in the family Polyomaviridae.Glycosaminoglycans and sialylated glycans sequentially facilitate Merkel cell polyomavirus infectious entry.Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan.Characterization of monoclonal antibodies specific for the Merkel cell polyomavirus capsidMucosal delivery of human papillomavirus pseudovirus-encapsidated plasmids improves the potency of DNA vaccination.Papillomavirus infection requires gamma secretase.Inhibition of gamma secretase blocks HPV infectionNeutralization serotyping of BK polyomavirus infection in kidney transplant recipientsComplete genome sequence of a tenth human polyomavirus.Human alpha-defensins block papillomavirus infectionEntry tropism of BK and Merkel cell polyomaviruses in cell cultureCross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2.WU polyomavirus in respiratory epithelial cells from lung transplant patient with Job syndromeGetting stronger: the relationship between a newly identified virus and Merkel cell carcinoma.Detection of human polyomavirus 7 in human thymic epithelial tumors.Antibody to the gp120 V1/V2 loops and CD4+ and CD8+ T cell responses in protection from SIVmac251 vaginal acquisition and persistent viremia.Hamburger polyomaviruses.Preclinical model to test human papillomavirus virus (HPV) capsid vaccines in vivo using infectious HPV/cottontail rabbit papillomavirus chimeric papillomavirus particles.Presence of human polyomavirus 6 in mutation-specific BRAF inhibitor-induced epithelial proliferations.Targeting the vaginal mucosa with human papillomavirus pseudovirion vaccines delivering simian immunodeficiency virus DNA.Positive correlation between Merkel cell polyomavirus viral load and capsid-specific antibody titer.Neutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibition.A protective and broadly cross-neutralizing epitope of human papillomavirus L2.Intravaginal immunization with HPV vectors induces tissue-resident CD8+ T cell responses.Murine skin and vaginal mucosa are similarly susceptible to infection by pseudovirions of different papillomavirus classifications and speciesArrangement of L2 within the papillomavirus capsid.Mucin biopolymers as broad-spectrum antiviral agents.Efficient intracellular assembly of papillomaviral vectorsBK polyomavirus genotypes represent distinct serotypes with distinct entry tropism.Merkel cell polyomavirus large T antigen disrupts host genomic integrity and inhibits cellular proliferation.
P50
Q21089628-1C37F916-7A08-4570-A95B-80FCDDAA7CEBQ21559417-67CF4B8C-0E08-402C-A467-B2DB16C613E3Q24633468-1E3A15B6-CE05-433C-B266-4C8010D5B35AQ24650632-5A772CEE-3AB8-4909-B931-D01D8173781EQ27684947-B70D405C-9C40-4013-95FB-76BF5772B935Q28485063-8EBB86CF-CFD0-49B6-9863-05C888188C88Q30484634-2814A69E-2AA1-484C-ACA2-7B0F02E39CE3Q33464965-1CD82672-12CB-4EDE-AFEB-0A4451E22466Q33834664-F0FD007C-F80F-4289-9898-FDD546461A8DQ33834872-3D1623EE-B0C5-4D1F-8E33-E42982C8D772Q33896114-14A0FEFB-EFB7-46E2-A3B6-485D50B41746Q33987448-B114EF77-C66B-4103-8DCD-9793B4598B61Q34004909-6BC8B434-D2E5-4B65-BF1D-4504F160EA0BQ34036827-79DC2D53-D81E-4C3B-9CFD-E5642F227142Q34075698-33138592-9073-4F38-8E5C-8CDF201F4708Q34178325-A62DAF89-06FB-4646-92A0-BB42014755DCQ34188410-EFE8FD83-368D-42B8-8ADC-000006039F5BQ34236633-5BA6F6C2-13A0-4FD4-A515-6E7A3EB618C8Q34299014-0EE53B6B-199F-4633-A1F7-1AED9BC9B9CFQ34334899-7BDECCE0-EFC5-421C-B473-2DFAD17C2A06Q34364604-AEF13111-C3CA-41E7-9B18-A18CD417610AQ34417608-805235DE-852F-4CFF-89ED-B492272B2F43Q34843445-A88AE14C-CF00-4056-B1DF-DA1B8BD4C45FQ34902922-D9A202CC-E9E9-40D6-A8BD-E1A09912CFBBQ35007667-E30226A2-011C-4709-A870-D053B9798331Q35105449-3116B209-972E-4348-A0FB-0F4AAAA4EF05Q35182743-7338A288-1301-4E72-A926-F9AA7810D417Q35185992-A05F51DD-288A-49AA-B172-439B0069B311Q35190909-D8EF90B3-8F89-43F1-8590-072FEA746D64Q35658952-538F2643-D474-4B62-843B-067BF8BBE9FEQ35667349-527DE59C-7DAF-48B2-B942-D96E68035CF4Q35947703-7B66D924-7539-4671-B96D-CBD6DCDDDC67Q36315086-AA75CEF8-B497-499C-9C00-6003F151CE35Q36498016-8EF10E18-A040-4824-B8F6-516F8E3FD611Q36554810-0C3476AB-A6B2-4E29-8E2A-8E9244CBA3B0Q36673336-1DB6597E-EDD8-451D-9A0A-FE31828100ADQ36683705-2F1A5608-DE73-4BA9-9779-7593B3BE4EE0Q36944399-32EB300A-80B6-4F0E-88A6-A4AE8C8D9F48Q37123173-6AEA32FD-71E9-4776-A149-EA6CCC1C503FQ37123294-24D4366F-0881-4CF9-9B6C-849E6D666363
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Christopher B Buck
@nl
Christopher B Buck
@sl
Christopher B. Buck
@en
Christopher B. Buck
@es
Christopher Buck
@fr
type
label
Christopher B Buck
@nl
Christopher B Buck
@sl
Christopher B. Buck
@en
Christopher B. Buck
@es
Christopher Buck
@fr
altLabel
Chris Buck
@en
Christopher B Buck
@en
prefLabel
Christopher B Buck
@nl
Christopher B Buck
@sl
Christopher B. Buck
@en
Christopher B. Buck
@es
Christopher Buck
@fr
P1053
G-8358-2017
P106
P1153
7102927846
P21
P31
P3829
P496
0000-0003-3165-8094